Separately, Raymond James cut shares of Teligent from a strong-buy rating to an outperform rating in a research note on Tuesday, March 19th.
Teligent stock opened at $0.76 on Thursday. The stock has a market cap of $41.00 million, a price-to-earnings ratio of -2.31 and a beta of 1.45. The company has a debt-to-equity ratio of 14.43, a quick ratio of 0.79 and a current ratio of 1.46. Teligent has a 52 week low of $0.66 and a 52 week high of $4.52.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Elk Creek Partners LLC grew its stake in shares of Teligent by 6.0% in the 4th quarter. Elk Creek Partners LLC now owns 4,880,589 shares of the company’s stock worth $6,686,000 after purchasing an additional 277,834 shares during the last quarter. Prosight Management LP grew its stake in shares of Teligent by 9.5% in the 4th quarter. Prosight Management LP now owns 3,547,607 shares of the company’s stock worth $4,860,000 after purchasing an additional 306,846 shares during the last quarter. BlackRock Inc. grew its stake in shares of Teligent by 0.5% in the 3rd quarter. BlackRock Inc. now owns 3,463,605 shares of the company’s stock worth $13,681,000 after purchasing an additional 16,198 shares during the last quarter. AMI Asset Management Corp grew its stake in shares of Teligent by 0.5% in the 1st quarter. AMI Asset Management Corp now owns 2,727,695 shares of the company’s stock worth $3,164,000 after purchasing an additional 13,403 shares during the last quarter. Finally, Vanguard Group Inc grew its stake in shares of Teligent by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 2,249,427 shares of the company’s stock worth $8,885,000 after purchasing an additional 15,800 shares during the last quarter. 64.59% of the stock is currently owned by institutional investors.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Further Reading: How a Back-End Load Mutual Fund Works
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.